Glaxo Creates Cell Research Institute to Speed Drug Development
This article is for subscribers only.
GlaxoSmithKline Plc will fund a research institute in Seattle to explore how cells function and how genes are controlled as the U.K.’s largest drugmaker seeks new ways to speed the discovery of medicines.
Glaxo will provide more than $95 million in cash and other resources to the Altius Institute in the first five years, the London-based drugmaker said today in a statement. It’s promising additional funding to apply the institute’s work to drug development projects.